Patent ID: 11873348
Assignee: ALLIGATOR BIOSCIENCE AB
Field: Biotechnology (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 2:
3. The method according to claim 1, wherein the bispecific antibody is capable of inducing:
(a) tumour-specific immune activation; and/or
(b) activation of dendritic cells; and/or
(c) internalisation of associated tumour debris and/or extracellular vesicles containing CEA antigens as well as tumour neoantigens; and/or
(d) cross-presentation of peptides derived from internalised tumour antigens on MHC; and/or
(e) priming and activation of effector T cells; and/or
(f) direct tumoricidal effects, selected from the list consisting of: apoptosis, necroptosis, antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).